NPY Y1 receptors exert opposite effects on corticotropin releasing factor and noradrenaline overflow from the rat hypothalamus in vitro

Hastings, Jacqueline; McClure-Sharp, Jill M.; Morris, Margaret J.

doi:10.1016/s0006-8993(00)02874-2

Cited by 34 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…That NPY actively participates in the osmotic regulation of hormone secretion is suggested by the increase in NPY mRNA and protein levels observed in the PVN and SON after chronic osmotic stimulation (Larsen et al, 1993). The presence of Y1R-and Y5R-ir in the parvocellular division further supports a role for these receptors in the regulation of corticotropin releasing hormone (Hastings et al, 2001) and thyrotrophin releasing hormone secretion (Michalkiewicz and Suzuki, 1994). As both Y1 and Y5 receptor-ir is present within cell bodies of the PVN and median eminence, it is likely that activation of either or both of these receptors directly influences the synthesis and release of hypothalamic releasing factors.…”

Section: Discussionmentioning

confidence: 81%

“…Both radioligand and in situ hybridization analyses reveal distinct patterns of distribution for each of these receptors providing anatomic correlates for the physiological role of NPY receptor activation. Of all the NPY receptors, the Y1 and Y5 receptor (Y1R, Y5R) subtypes have received significant attention based on their ability to increase food intake (Schaffhauser et al, 1997;Duhault et al, 2000), modulate anxiety (Wahlestedt et al, 1993;Heilig et al, 1993), and regulate hormone secretions (Leupen et al, 1997;Hastings et al, 2001). The Y1 receptor was the first receptor to be cloned and is perhaps the best characterized receptor for NPY (Eva et al, 1990(Eva et al, , 1992.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry

Wolak

DeJoseph

Cator

et al. 2003

J of Comparative Neurology

183

198

View full text Add to dashboard Cite

Neuropeptide Y (NPY) Y1 and Y5 receptor subtypes mediate many of NPY's diverse actions in the central nervous system. The present studies use polyclonal antibodies directed against the Y1 and Y5 receptors to map and compare the relative distribution of these NPY receptor subtypes within the rat brain. Antibody specificity was assessed by using Western analysis, preadsorption of the antibody with peptide, and preimmune serum controls. Immunostaining for the Y1 and Y5 receptor subtypes was present throughout the rostral-caudal aspect of the brain with many regions expressing both subtypes: cerebral cortex, hippocampus, hypothalamus, thalamus, amygdala, and brainstem. Further studies using double-label immunocytochemistry indicate that Y1R immunoreactivity (-ir) and Y5R-ir are colocalized in the cerebral cortex and caudate putamen. Y1 receptor ir was evident in the central amygdala, whereas both Y1- and Y5-immunoreactive cells and fibers were present in the basolateral amygdala. Corresponding with the physiology of NPY in the hypothalamus, both Y1R- and Y5R-ir was present within the paraventricular (PVN), supraoptic, arcuate nuclei, and lateral hypothalamus. In the PVN, Y5R-ir and Y1R-ir were detected in cells and fibers of the parvo- and magnocellular divisions. Intense immunostaining for these receptors was observed within the locus coeruleus, A1-5 and C1-3 nuclei, subnuclei of the trigeminal nerve and nucleus tractus solitarius. These data provide a detailed and comparative mapping of Y1 and Y5 receptor subtypes within cell bodies and nerve fibers in the brain which, together with physiological and electrophysiological studies, provide a better understanding of NPY neural circuitries.

show abstract

Section: Discussionmentioning

confidence: 81%

mentioning

confidence: 99%

Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry

Wolak

DeJoseph

Cator

et al. 2003

J of Comparative Neurology

183

198

View full text Add to dashboard Cite

show abstract

“…Activation of ACTH and/or corticosterone release has been observed after icv administration of Y2 and Y5 (32, 33) but not Y4 agonists (33). Studies by Hastings et al (34) showed that NPY-induced increases in CRH release from hypothalamic explants can be blocked by prior treatment with the Y1 antagonist GR231118. Tebbe et al (35) supported the role for PVN NPY Y1 receptors in CRH-mediated inhibition of gastric acid secretion.…”

Section: Discussionmentioning

confidence: 99%

Involvement of Neuropeptide Y Y1 Receptors in the Regulation of Neuroendocrine Corticotropin-Releasing Hormone Neuronal Activity

et al. 2007

View full text Add to dashboard Cite

The neuroendocrine parvocellular CRH neurons in the paraventricular nucleus (PVN) of the hypothalamus are the main integrators of neural inputs that initiate hypothalamic-pituitary-adrenal (HPA) axis activation. Neuropeptide Y (NPY) expression is prominent within the PVN, and previous reports indicated that NPY stimulates CRH mRNA levels. The purpose of these studies was to examine the participation of NPY receptors in HPA axis activation and determine whether neuroendocrine CRH neurons express NPY receptor immunoreactivity. Infusion of 0.5 nmol NPY into the third ventricle increased plasma corticosterone levels in conscious rats, with the peak of hormone levels occurring 30 min after injection. This increase was prevented by pretreatment with the Y1 receptor antagonist BIBP3226. Immunohistochemistry showed that CRH-immunoreactive neurons coexpressed Y1 receptor immunoreactivity (Y1r-ir) in the PVN, and a majority of these neurons (88.8%) were neuroendocrine as determined by ip injections of FluoroGold. Bilateral infusion of the Y1/Y5 agonist, [leu(31)pro(34)]NPY (110 pmol), into the PVN increased c-Fos and phosphorylated cAMP response element-binding protein expression and elevated plasma corticosterone levels. Increased expression of c-Fos and phosphorylated cAMP response element-binding protein was observed in populations of CRH/Y1r-ir cells. The current findings present a comprehensive study of NPY Y1 receptor distribution and activation with respect to CRH neurons in the PVN. The expression of NPY Y1r-ir by neuroendocrine CRH cells suggests that alterations in NPY release and subsequent activation of NPY Y1 receptors plays an important role in the regulation of the HPA.

show abstract

“…Using rat hypothalamic synaptosomes, Martire et al [135] demonstrated that NPY 13-36 induces a concentration-dependent inhibition of the 4-aminopyridineevoked [ 3 H]NE release, and they suggested that this effect is independent of calcium entry. More recently, Hastings et al [235] identified a direct neuromodulatory action of NPY on the overflow of CRF and NE in the hypothalamus of adult rats. Afterwards, the same authors showed that perfusion with [Leu 31 ,Pro 34 ]NPY significantly reduced NE overflow from the hypothalamus and medulla [236].…”

Section: Npy Releasementioning

confidence: 99%

The Putative Neuroprotective Role of Neuropeptide Y in the Central Nervous System

Silva

Xapelli

Grouzmann³

et al. 2005

CDTCNSND

View full text Add to dashboard Cite

Neuropeptide Y (NPY) is one of the most abundant and widely distributed neuropeptides in the mammalian central nervous system (CNS). An overview of the distribution of the G-protein coupled NPY receptor family (Y(1), Y(2), Y(4), Y(5) receptors) in the brain is described. The coexistence of NPY with other neurotransmitters and its wide distribution in several brain areas predict the high importance of NPY as a neuromodulator. Thus, the effect of NPY on the release of several neurotransmitters such as glutamate, gamma-aminobutyric acid (GABA), norepinephrine (NE), dopamine, somastotatin (SOM), serotonin (5-HT), nitric oxide (NO), growth hormone (GH) and corticotropin releasing factor (CRF) is reviewed. A neuroprotective role for NPY under physiological conditions and during hyperactivity such as epileptic-seizures has been suggested. We have shown previously that NPY inhibits glutamate release evoked from hippocampal nerve terminals and has a neuroprotective effect in rat organotypic hippocampal cultures exposed to an excitotoxic insult. Moreover, changes in NPY levels have been observed in different pathological conditions such as brain ischemia and neurodegenerative diseases (Huntington's, Alzheimer's and Parkinson's diseases). Taken together, these studies suggest that NPY and NPY receptors may represent pharmacological targets in different pathophysiological conditions in the CNS.

show abstract

NPY Y1 receptors exert opposite effects on corticotropin releasing factor and noradrenaline overflow from the rat hypothalamus in vitro

Cited by 34 publications

References 39 publications

Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry

Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry

Involvement of Neuropeptide Y Y1 Receptors in the Regulation of Neuroendocrine Corticotropin-Releasing Hormone Neuronal Activity

The Putative Neuroprotective Role of Neuropeptide Y in the Central Nervous System

Contact Info

Product

Resources

About